跳至主要内容
临床试验/NCT01099774
NCT01099774已完成3 期

Safety and Efficacy of Different Formulations of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

Allergan0 个研究点目标入组 597 人开始时间: 2010年5月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
Allergan
入组人数
597
主要终点
Average Eye IOP at Week 12

研究概览

简要总结

This study will evaluate the safety and efficacy of bimatoprost 0.03% formulation B ophthalmic solution with LUMIGAN® (bimatoprost ophthalmic solution 0.03%) once daily for 12 weeks in patients with glaucoma or ocular hypertension

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patient has ocular hypertension or glaucoma in both eyes
  • Requires IOP-lowering therapy in each eye

排除标准

  • Active or recurrent eye disease that would interfere with interpretation of study data in either eye
  • History of any eye surgery or laser in either eye within 6 months
  • Required chronic use of other eye medications during the study
  • Anticipated wearing of contact lenses during the study.
  • Intermittent use of oral, intramuscular, or intravenous corticosteroids within 21 days

研究组 & 干预措施

Bimatoprost 0.03% Formulation B Ophthalmic Solution

Experimental

Bimatoprost 0.03% Formulation B Ophthalmic Solution

干预措施: Bimatoprost 0.03% Formulation B Ophthalmic Solution (Drug)

Bimatoprost 0.03% Ophthalmic Solution

Active Comparator

Bimatoprost 0.03% Ophthalmic Solution

干预措施: Bimatoprost 0.03% Ophthalmic Solution (Drug)

结局指标

主要结局

Average Eye IOP at Week 12

时间窗: Baseline, Week 12

Average Eye IOP at Week 12 . IOP is a measurement of fluid pressure inside the eye. IOP measurements were evaluated at hours 0, 2, and 8 in both eyes and the average IOP of both eyes at each time point were reported. Baseline data are included for reference only.

Average Eye IOP at Week 6

时间窗: Week 6

Average Eye IOP at Week 6 . IOP is a measurement of fluid pressure inside the eye. IOP measurements were evaluated at hours 0, 2, and 8 in both eyes and the average IOP of both eyes at each time point were reported.

Change From Baseline in Worse Eye Intraocular Pressure (IOP) at Week 12

时间窗: Baseline, Week 12

Change from baseline in worse eye IOP at Week 12 . IOP is a measurement of fluid pressure inside the eye. IOP measurements in the worse eye were evaluated at hours 0, 2, and 8. A negative number change from baseline indicated a reduction in IOP, and a positive number change from baseline indicated an increase in IOP.

Average Eye IOP at Week 2

时间窗: Week 2

Average Eye IOP at Week 2 . IOP is a measurement of fluid pressure inside the eye. IOP measurements were evaluated at hours 0, 2, and 8 in both eyes and the average IOP of both eyes at each time point were reported.

次要结局

未报告次要终点

研究者

发起方
Allergan
申办方类型
Industry
责任方
Sponsor

相似试验